The company’s imaging system was found to be insufficiently effective.
TK-Signal Ltd. has suspended development of its most advanced product, an imaging system for diagnosing cancer. The product was due to begin clinical trials later this year, but has been found to be insufficiently effective and has been sent back to the laboratory for improvement.
TK-Signal’s shareholders include Hadasit Bio Holdings Ltd. (TASE:HDST) and ProSeed Venture Capital Fund (TASE:PRSD).
Published by Globes [online], Israel business news - www.globes.co.il - on July 5, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007